Cytotoxicity and -glucosidase inhibition studies of Cu(II) and Ni(II) salicylhydroxamic acid complexes


  • Latifah Robbaniyyah Hassan Universiti Teknologi MARA
  • Hadariah Bahron Universiti Teknologi MARA
  • Kalavathy Ramasamy Universiti Teknologi MARA
  • Amalina Mohd Tajuddin Universiti Teknologi MARA



salicylhydroxamic acid, copper(II), nickel(II), cytotoxicity, -glucosidase


Hydroxamic acids (RCONHOH) are weak acids that can exist naturally or synthetically. These acids are easy to deprotonate and produce hydroxamate ions. The syntheses, physico-chemical and characterization of salicylhydroxamic acid (SHA) and its copper(II) and nickel(II) complexes were reported herein. The metal complexes were synthesized by condensation reaction of SHA with metal salts in 2:1 molar ratio. SHA and its metal complexes were characterized by elemental analysis, infrared spectroscopy, 1H and 13C NMR, UV-Vis, TGA, magnetic susceptibility and molar conductance. From IR and magnetic susceptibility, each complexes coordinated to the metal via oxygen atoms (O,O) in a bidentate manner to form octahedral geometries. The molar conductance values suggested that all complexes were non-electrolytes. A cytotoxicity study against HCT116 displayed that Cu(II) and Ni(II) complexes have better anticancer than their parent ligands, SHA but not categorized as potent anticancer agents. Both complexes have better inhibition towards a-glucosidase compared to acarbose, suggesting that Cu(II) and Ni(II) complexes have potential as antidiabetic agents.

Author Biographies

Latifah Robbaniyyah Hassan, Universiti Teknologi MARA

Faculty of Applied Sciences

Hadariah Bahron, Universiti Teknologi MARA

Institute of Research Management & Innovation (IRMI)

Kalavathy Ramasamy, Universiti Teknologi MARA

Faculty of Pharmacy

Amalina Mohd Tajuddin, Universiti Teknologi MARA

Atta-ur-Rahman Institute for Natural Product Discovery (AuRIns)


Chauhan, S., Deepak, Garg, S., Verma, K. K. 2016. Study on 4-Methoxybenzohydroxamate complexes of Aryltellurium (IV) and

Diaryltellurium (IV). Int. J. Chem. Sci. 14(1), 269–282.

Desoize, B. 2002. Cancer and metals and metal compounds: Part 1 – Carcinogenesis. Crit Rev. Oncol. Hematol., 42(1), 1–3.

Fazary, A. E. 2014. Metal complexes of salicylhydroxamic acid and 1,10-phenanthroline; equilibrium and antimicrobial activity studies. B. Chem. Soc. Ethiopia, 28(3), 393–402.

Graisa, A., Farina, Y., Yousif, E., Kassem, M. 2008. Synthesis and characterization of Some Diorganotin (IV) complexes of n-tolyl-mnitrobenzohydroxamic acid. ARPN J. Eng. Appl. Sci., 3(6), 47–50.

Haratake, M., Fukunaga, M., Ono, M., Nakayama, M. 2005. Synthesis of vanadium (IV,V) hydroxamic acid complexes and in vivo assessment of their insulin-like activity. J. Biol. Inorg. Chem., 10(3), 250–258.

Kumar, P., Narasimhan, B., Ramasamy, K., Mani, V., Mishra, R., Majeed, A. 2015. Synthesis, antimicrobial, anticancer evaluation and QSAR studies of 3/4-bromo benzohydrazide derivatives. Curr. Top. Med. Chem., 15(11), 1050–1064.

Marmion, C. J., Griffith, D., Nolan, K. B. 2004. Hydroxamic acids - An intriguing family of enzyme inhibitors and biomedical ligands. Eur. J. Inorg. Chem. 3003–3016.

Ndagi, U., Mhlongo, N. N., Soliman, M. E. 2017. Metal complexes in cancer therapy – An update from drug design perspective. Drug. Des. Devel. Ther., 11, 599–616.

Pakchung, A. A. H., Soe, C. Z., Lifa, T., Codd, R. 2011. Complexes formed in solution between vanadium (IV)/(V) and the cyclic dihydroxamic acid putrebactin or linear suberodihydroxamic acid. Inorg. Chem., 50(13), 5978–5989.

Sharma, N., Kumari, M., Kumar, V., Chaudhry, S. C., Kanwar, S. S. 2010. Synthesis, characterization, and antibacterial activity of vanadium(IV) complexes of hydroxamic acids. J. Coord. Chem., 63(1), 176–184.

Sharma, N., Kumari, M., Sharma, R. 2012. Thermoanalytical studies of oxovanadium (IV) hydroxamate complexes. J. Therm. Anal. Calorim., 107(1), 225–229.

Sharma, R., Sharma, N. 2012. Thermal studies of some biologically active oxovanadium (IV) complexes containing 8-hydroxyquinolinate and hydroxamate ligands. J. Therm. Anal. Calorim., 110(2), 539–543.

Sharma, S., Sharma, N. 2013. Biological activity of bis(nicotinohydroxamato) oxidovanadium(IV) complex. Der Chemica Sinica, 4(4), 87–96.

Shotor, S. N. M., Kassim, K., Bahron, H., Tajuddin, A. M., Yusof, F. Z. 2010. In-vitro cytotoxicity studies of vanadyl complexes with hydroxamic acid series. In 2010 International Conference on Science and Social Research (CSSR 2010), Kuala Lumpur, Malaysia. 1283–1286.

Srivastava, K. P., Singh, B., Akbar, A. 2009. Synthesis and characterisation of CoII complexes of dibasic tetradentate (OO’NO donor) ligand. Int. J. Chemtech Res., 1(1), 71–79.

Temel, H., Sekerci, M. 2001. Novel complexes of manganese(III), cobalt(II), copper(II) and zinc(II) with Schiff base derived from 1,2-bis(p-aminophenoxy)ethane and salicylaldehyde. Synth. React. Inorg. M., 31(5), 849–857.

Tripathi, I. P., Dwivedi, A., Mishra, M. 2017. Metal-based α-glucosidase inhibitors : Synthesis, characterization and α-glucosidase inhibition activity of transition metal complexes. Asian Med. Health, 2(3), 1–14.